HemaCare Corporation (“HemaCare” or the “Company”) operates in two primary business segments – the blood products segment and the therapeutic services segment. The blood products segment includes the sale of apheresis platelets on an exclusive basis to The American National Red Cross (“ARC”), and sales of other blood products to research, cellular therapy and other health and biotech related organizations. Prior to the sale of our red blood cell collection business to ARC in July 2011, the Company also sold blood products to hospitals, operated and managed donor centers and mobile donor vehicles to collect blood products from volunteer donors, and purchased blood products from other suppliers for resale to customers. Revenues from the sale of apheresis platelets to ARC and revenues from research projects and cellular therapy collections are included in the blood products segment.
Company profile
Ticker
HEMA
Exchange
Website
CEO
Peter C. van der Wal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
953280412
Latest filings (excl ownership)
15-12G
Securities registration termination
6 Apr 12
10-K
2011 FY
Annual report
5 Apr 12
NT 10-K
Notice of late annual filing
30 Mar 12
EFFECT
Notice of effectiveness
28 Mar 12
POS AM
Prospectus update (post-effective amendment)
20 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 12
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Mar 12
Latest ownership filings
No filings